Strategic Alliance Between Apertura and Viralgen to Advance Gene Therapy Manufacturing Apertura Gene Therapy and Viralgen have partnered to manufacture TfR1 CapX, a breakthrough capsid for gene therapies aimed at central nervous system diseases.

Strategic Alliance Between Apertura and Viralgen to Advance Gene Therapy Manufacturing #USA #New_York #Viralgen #Apertura_Gene_Therapy #TfR1_CapX

Apertura Gene Therapy and Viralgen Unite for Advanced Gene Therapy Manufacturing Apertura Gene Therapy teams up with Viralgen to manufacture the innovative TfR1 CapX for treating central nervous system diseases, enhancing gene therapy prospects.

Apertura Gene Therapy and Viralgen Unite for Advanced Gene Therapy Manufacturing #USA #New_York #Viralgen #Apertura_Gene_Therapy #TfR1_CapX

Apertura Gene Therapy and Viralgen Team Up for Innovative Gene Therapy Development Apertura and Viralgen forge a strategic partnership to manufacture the new TfR1 CapX capsid, enhancing gene therapies for central nervous system diseases.

Apertura Gene Therapy and Viralgen Team Up for Innovative Gene Therapy Development #USA #New_York #Viralgen #Apertura_Gene_Therapy #TfR1_CapX

Apertura Gene Therapy Introduces Open Aperture Program for Enhanced Research Access to TfR1 CapX Apertura Gene Therapy has launched the Open Aperture program, providing free access to its TfR1 CapX capsid for academic researchers to facilitate important CNS research.

Apertura Gene Therapy Introduces Open Aperture Program for Enhanced Research Access to TfR1 CapX #USA #New_York #Apertura_Gene_Therapy #TfR1_CapX #Open_Aperture

Apertura Gene Therapy Partners To Enhance CNS Treatment with Innovative Capsids Apertura Gene Therapy has secured licensing agreements to leverage its novel AAV capsid technology, promising a breakthrough in CNS therapies.

Apertura Gene Therapy Partners To Enhance CNS Treatment with Innovative Capsids #USA #New_York #CNS_disorders #Apertura_Gene_Therapy #TfR1_CapX

Apertura Gene Therapy Unveils Breakthrough AAV Capsid Progress at ASGCT 2025 Apertura Gene Therapy highlights its innovative AAV capsid, TfR1 CapX, at ASGCT, showcasing advancements in targeting neurological disorders through gene therapy.

Apertura Gene Therapy Unveils Breakthrough AAV Capsid Progress at ASGCT 2025 #United_States #New_Orleans #ASGCT #Apertura_Gene #TfR1_CapX